Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription 15.10.2018 1 Am J Clin Oncol 1 Ann Oncol 2 Ann Surg Oncol 2 Ann Thorac Surg 3 Anticancer Res 1 Arch Bronconeumol 1 Arch Pathol Lab Med 4 BMC Cancer 1 Cancer Chemother Pharmacol 1 Cancer Epidemiol Biomarkers Prev 4 Cancer Sci 1 Chest 1 Clin Cancer Res 2 Clin Lung Cancer 3 Clin Nucl Med 1 Eur J Cardiothorac Surg 3 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Surg Oncol 4 J Thorac Oncol 1 JAMA Oncol 3 Lancet Respir Med 2 Lung Cancer 4 Oncogene 3 Oncol Rep 5 PLoS One 1 Proc Natl Acad Sci U S A 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. KARANTH S, Rajan SS, Revere FL, Sharma G, et al
   Factors Affecting Racial Disparities in End-of-Life Care Costs Among Lung Cancer Patients: A SEER-Medicare-based Study.
   Am J Clin Oncol. 2018 Oct 8. doi: 10.1097/COC.0000000000000485.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

2. PLANCHARD D, Popat S, Kerr K, Novello S, et al
   Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
   Ann Oncol. 2018;29.
   PubMed     Text format    
   
   

   
   Ann Surg Oncol

3. LEE SY, Park JY
   GLUT1 Variants for Predicting Prognosis After Surgery in Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2018 Oct 3. pii: 10.1245/s10434-018-6847.
   PubMed     Text format    
   
   
4. OKADA S, Inoue M
   ASO Author Reflections: Prognostic Nutritional Index-Based Risk Stratification for Lung Cancer.
   Ann Surg Oncol. 2018 Oct 10. pii: 10.1245/s10434-018-6884.
   PubMed     Text format    
   
   

   
   Ann Thorac Surg

5. SIHOE ADL
   Uniportal Lung Cancer Surgery: The State of the Evidence.
   Ann Thorac Surg. 2018 Oct 6. pii: S0003-4975(18)31418.
   PubMed     Text format     Abstract available
   
   
6. GAMBAZZI F, Frey LD, Bruehlmeier M, Janthur WD, et al
   Comparing Two Imaging Methods for Follow-up of Lung Cancer Treatment: A Randomized Pilot Study.
   Ann Thorac Surg. 2018 Oct 4. pii: S0003-4975(18)31358.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

7. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
   Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
   Anticancer Res. 2018;38:6023-6026.
   PubMed     Text format     Abstract available
   
   
8. YOON N, Kim J, Maeng LS, Ahn JH, et al
   Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
   Anticancer Res. 2018;38:6003-6008.
   PubMed     Text format     Abstract available
   
   
9. FREEMAN J, Crowley PD, Foley AG, Gallagher HC, et al
   Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery.
   Anticancer Res. 2018;38:5599-5606.
   PubMed     Text format     Abstract available
   
   

   
   Arch Bronconeumol

10. ROCHA P, Arriola E
    Immunotherapy is Here to Stay: A New Treatment Paradigm in Lung Cancer.
    Arch Bronconeumol. 2018 Oct 5. pii: S0300-2896(18)30331.
    PubMed     Text format    
    
    

    
    Arch Pathol Lab Med

11. THUNNISSEN E
    How to Validate Predictive Immunohistochemistry Testing in Pathology?: A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer.
    Arch Pathol Lab Med. 2018 Oct 11. doi: 10.5858/arpa.2018-0410.
    PubMed     Text format    
    
    

    
    BMC Cancer

12. LIU L, Shi M, Wang Z, Lu H, et al
    A molecular and staging model predicts survival in patients with resected non-small cell lung cancer.
    BMC Cancer. 2018;18:966.
    PubMed     Text format     Abstract available
    
    
13. QIN RS, Zhang ZH, Zhu NP, Chen F, et al
    Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
    BMC Cancer. 2018;18:967.
    PubMed     Text format     Abstract available
    
    
14. WANG X, Zamdborg L, Ye H, Grills IS, et al
    A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
    BMC Cancer. 2018;18:962.
    PubMed     Text format     Abstract available
    
    
15. TACHIHARA M, Negoro S, Inoue T, Tamiya M, et al
    Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
    BMC Cancer. 2018;18:946.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

16. HE Y, Xie H, Yu P, Jiang S, et al
    FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
    Cancer Chemother Pharmacol. 2018 Oct 9. pii: 10.1007/s00280-018-3697.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

17. BROWN D, Zingone A, Yu Y, Zhu B, et al
    Relationship between circulating inflammation proteins and lung cancer diagnosis in the National Lung Screening Trial.
    Cancer Epidemiol Biomarkers Prev. 2018 Oct 8. pii: 1055-9965.EPI-18-0598.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Sci

18. ZHAO X, Li X, Zhou L, Ni J, et al
    LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3.
    Cancer Sci. 2018;109:3068-3079.
    PubMed     Text format     Abstract available
    
    
19. KATO Y, Ninomiya K, Ohashi K, Tomida S, et al
    Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Cancer Sci. 2018;109:3149-3158.
    PubMed     Text format     Abstract available
    
    
20. LIU M, Jiang L, Fu X, Wang W, et al
    Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy.
    Cancer Sci. 2018;109:3055-3067.
    PubMed     Text format     Abstract available
    
    
21. MAEMURA K, Watanabe K, Ando T, Hiyama N, et al
    Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma.
    Cancer Sci. 2018;109:3326-3335.
    PubMed     Text format     Abstract available
    
    

    
    Chest

22. DE LA HOZ RE, Weissman DN
    Consideration of Occupational and Environmental Lung Carcinogen Exposures for Lung Cancer Screening Using Low-Dose Chest CT.
    Chest. 2018;154:996-997.
    PubMed     Text format    
    
    

    
    Clin Cancer Res

23. XIE Y, Lu W, Wang S, Tang X, et al
    Validation of the 12-gene predictive signature for Adjuvant Chemotherapy Response in Lung Cancer.
    Clin Cancer Res. 2018 Oct 4. pii: 1078-0432.CCR-17-2543.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

24. PIRKER R, Filipits M
    Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives.
    Clin Lung Cancer. 2018 Sep 24. pii: S1525-7304(18)30261.
    PubMed     Text format     Abstract available
    
    
25. NG TL, Yu H, Smith DE, Boyle TA, et al
    Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.
    Clin Lung Cancer. 2018 Sep 7. pii: S1525-7304(18)30234.
    PubMed     Text format     Abstract available
    
    

    
    Clin Nucl Med

26. OUYANG ML, Tang K, Xu MM, Lin J, et al
    Prediction of Occult Lymph Node Metastasis Using Tumor-to-Blood Standardized Uptake Ratio and Metabolic Parameters in Clinical N0 Lung Adenocarcinoma.
    Clin Nucl Med. 2018;43:715-720.
    PubMed     Text format     Abstract available
    
    
27. WU X, Zhang C, Huang Y, Wang H, et al
    Maxillofacial Spindle Cell Sarcoma With Lung Metastases on FDG PET/CT Imaging.
    Clin Nucl Med. 2018 Jul 14. doi: 10.1097/RLU.0000000000002206.
    PubMed     Text format     Abstract available
    
    
28. HU Y, Wu D, Tian C, Wei Q, et al
    Diagnosis of Multiple Primary Intestinal-Type Adenocarcinoma in the Lung by 18F-FDG PET/CT.
    Clin Nucl Med. 2018 Jul 12. doi: 10.1097/RLU.0000000000002171.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cardiothorac Surg

29. SUN C, Anraku M, Karasaki T, Kuwano H, et al
    Low truncal muscle area on chest computed tomography: a poor prognostic factor for the cure of early-stage non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2018 Oct 4. pii: 5115406. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

30. MATSUO N, Azuma K, Hattori S, Ohtake J, et al
    Association between soluble immune mediators and tumor responses in patients with non-small cell lung cancer treated with anti-PD-1 inhibitor.
    Int J Cancer. 2018 Oct 11. doi: 10.1002/ijc.31923.
    PubMed     Text format     Abstract available
    
    
31. BOYAR CETINKAYA R, Aagnes B, Myklebust TA, Thiis-Evensen E, et al
    Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study.
    Int J Cancer. 2018;142:1139-1147.
    PubMed     Text format     Abstract available
    
    
32. PASSIGLIA F, Galvano A, Rizzo S, Incorvaia L, et al
    Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
    Int J Cancer. 2018;142:1277-1284.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

33. YIN X, Mason J, Lobachevsky PN, Munforte L, et al
    Radiotherapy Modulates DNA Repair Efficiency in Peripheral Blood Mononuclear Cells Of Patients With Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Oct 9. pii: S0360-3016(18)33833.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

34. YAN X, Wang Q, Wang H, Li P, et al
    Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
    J Cancer Res Clin Oncol. 2018 Oct 6. pii: 10.1007/s00432-018-2764.
    PubMed     Text format     Abstract available
    
    

    
    J Surg Oncol

35. NEWTON AD, Predina JD, Nie S, Low PS, et al
    Intraoperative fluorescence imaging in thoracic surgery.
    J Surg Oncol. 2018;118:344-355.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Oncol

36. LEVY A, Le Pechoux C, Mistry H, Martel-Lafay I, et al
    Prophylactic cranial irradiation for limited-stage small-cell lung cancer patients: secondary findings from the prospective randomized phase 3 CONVERT trial.
    J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33171.
    PubMed     Text format     Abstract available
    
    
37. RAMALINGAM S, Dinan MA, Crawford J
    Survival comparison in patients with Stage IV lung cancer in Academic versus Community Centers in the United States.
    J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33117.
    PubMed     Text format     Abstract available
    
    
38. CHAE YK, Oh MS
    Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions.
    J Thorac Oncol. 2018 Oct 5. pii: S1556-0864(18)33174.
    PubMed     Text format     Abstract available
    
    
39. SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
    Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33173.
    PubMed     Text format     Abstract available
    
    

    
    JAMA Oncol

40. BOOZALIS E, Kwatra SG, Marrone KA
    Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 4. pii: 2704206. doi: 10.1001/jamaoncol.2018.4485.
    PubMed     Text format    
    
    

    
    Lancet Respir Med

41. PETERSEN I
    Predictive pathology of lung cancer immunotherapy response.
    Lancet Respir Med. 2018;6:731-733.
    PubMed     Text format    
    
    
42. FURLOW B
    Tobacco control, lung cancer, and tuberculosis in Singapore.
    Lancet Respir Med. 2018;6:741-742.
    PubMed     Text format    
    
    
43. REYNOSO C
    Peter Czanyo: lung cancer survivor.
    Lancet Respir Med. 2018;6:746.
    PubMed     Text format    
    
    

    
    Lung Cancer

44. XU R, Zhu J
    Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
    Lung Cancer. 2018 Sep 24. pii: S0169-5002(18)30577.
    PubMed     Text format    
    
    
45. MATYS T, Drury R, David S, Rassl DM, et al
    Corrigendum to "Routine preoperative brain CT in resectable non-small cell lung cancer-Ten years experience from a tertiary UK thoracic center" [Lung Cancer 122 (August) (2018) 195-199].
    Lung Cancer. 2018 Oct 1. pii: S0169-5002(18)30575.
    PubMed     Text format    
    
    

    
    Oncogene

46. SHIMIZU M, Tanaka N
    IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells.
    Oncogene. 2018 Oct 10. pii: 10.1038/s41388-018-0533.
    PubMed     Text format     Abstract available
    
    
47. ZHENG X, Chi J, Zhi J, Zhang H, et al
    Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
    Oncogene. 2018;37:502-511.
    PubMed     Text format     Abstract available
    
    
48. ROWSON-HODEL AR, Wald JH, Hatakeyama J, O'Neal WK, et al
    Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer.
    Oncogene. 2017 Sep 11. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available
    
    
49. CORKERY DP, Clarke LE, Gebremeskel S, Salsman J, et al
    Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking.
    Oncogene. 2018;37:174-184.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

50. HE RQ, Gao L, Ma J, Li ZY, et al
    Oncogenic role of miR1835p in lung adenocarcinoma: A comprehensive study of qPCR, in vitro experiments and bioinformatic analysis.
    Oncol Rep. 2018;40:83-100.
    PubMed     Text format     Abstract available
    
    
51. HU BD, Guo J, Ye YZ, Du T, et al
    Specific inhibitor of Notch3 enhances the sensitivity of NSCLC cells to gemcitabine.
    Oncol Rep. 2018;40:155-164.
    PubMed     Text format     Abstract available
    
    
52. ZHANG W, Cui Q, Qu W, Ding X, et al
    TRIM58/cg26157385 methylation is associated with eight prognostic genes in lung squamous cell carcinoma.
    Oncol Rep. 2018;40:206-216.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

53. LIN PY, Chang YJ, Chen YC, Lin CH, et al
    Anti-cancer effects of 3,5-dimethylaminophenol in A549 lung cancer cells.
    PLoS One. 2018;13:e0205249.
    PubMed     Text format     Abstract available
    
    
54. SCHERNBERG A, Mezquita L, Boros A, Botticella A, et al
    Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer.
    PLoS One. 2018;13:e0204490.
    PubMed     Text format     Abstract available
    
    
55. OWENS CA, Peterson CB, Tang C, Koay EJ, et al
    Lung tumor segmentation methods: Impact on the uncertainty of radiomics features for non-small cell lung cancer.
    PLoS One. 2018;13:e0205003.
    PubMed     Text format     Abstract available
    
    
56. YAMAMOTO T, Kadoya N, Morishita Y, Sato Y, et al
    Assessment and agreement of the CT appearance pattern and its severity grading of radiation-induced lung injury after stereotactic body radiotherapy for lung cancer.
    PLoS One. 2018;13:e0204734.
    PubMed     Text format     Abstract available
    
    
57. WANG J, Duan Y, Meng QH, Gong R, et al
    Integrated analysis of DNA methylation profiling and gene expression profiling identifies novel markers in lung cancer in Xuanwei, China.
    PLoS One. 2018;13:e0203155.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

58. MORGAN MJ, Fitzwalter BE, Owens CR, Powers RK, et al
    Metastatic cells are preferentially vulnerable to lysosomal inhibition.
    Proc Natl Acad Sci U S A. 2018;115:E8479-E8488.
    PubMed     Text format     Abstract available
    
    

    
    Semin Oncol

59. SHINDE A, Li R, Kim J, Salgia R, et al
    Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.
    Semin Oncol. 2018 Jul 1. pii: S0093-7754(18)30008.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: